25 XP   0   0   10

Dermapharm Holding SE
Buy, Hold or Sell?

Let's analyse Dermapharm Holding SE together

PenkeI guess you are interested in Dermapharm Holding SE. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Dermapharm Holding SE. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Dermapharm Holding SE

I send you an email if I find something interesting about Dermapharm Holding SE.

Quick analysis of Dermapharm Holding SE (30 sec.)










What can you expect buying and holding a share of Dermapharm Holding SE? (30 sec.)

How much money do you get?

How much money do you get?
€2.23
When do you have the money?
1 year
How often do you get paid?
69.0%

What is your share worth?

Current worth
€10.12
Expected worth in 1 year
€10.36
How sure are you?
89.7%

+ What do you gain per year?

Total Gains per Share
€2.33
Return On Investment
7.2%

For what price can you sell your share?

Current Price per Share
€32.50
Expected price per share
€31.50 - €34.96
How sure are you?
50%

1. Valuation of Dermapharm Holding SE (5 min.)




Live pricePrice per Share (EOD)

€32.50

Intrinsic Value Per Share

€31.13 - €35.83

Total Value Per Share

€41.26 - €45.96

2. Growth of Dermapharm Holding SE (5 min.)




Is Dermapharm Holding SE growing?

Current yearPrevious yearGrowGrow %
How rich?$580.8m$540.6m$43.4m7.4%

How much money is Dermapharm Holding SE making?

Current yearPrevious yearGrowGrow %
Making money$16.6m$35.7m-$19.1m-115.2%
Net Profit Margin4.9%13.1%--

How much money comes from the company's main activities?

3. Financial Health of Dermapharm Holding SE (5 min.)




What can you expect buying and holding a share of Dermapharm Holding SE? (5 min.)

Welcome investor! Dermapharm Holding SE's management wants to use your money to grow the business. In return you get a share of Dermapharm Holding SE.

What can you expect buying and holding a share of Dermapharm Holding SE?

First you should know what it really means to hold a share of Dermapharm Holding SE. And how you can make/lose money.

Speculation

The Price per Share of Dermapharm Holding SE is €32.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Dermapharm Holding SE.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Dermapharm Holding SE, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €10.12. Based on the TTM, the Book Value Change Per Share is €0.06 per quarter. Based on the YOY, the Book Value Change Per Share is €0.17 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.52 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Dermapharm Holding SE.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.05-0.2%0.311.0%0.662.0%0.561.7%0.531.6%
Usd Book Value Change Per Share0.000.0%0.060.2%0.180.5%0.290.9%0.371.1%
Usd Dividend Per Share0.000.0%0.561.7%2.317.1%1.103.4%0.812.5%
Usd Total Gains Per Share0.000.0%0.621.9%2.497.6%1.394.3%1.193.6%
Usd Price Per Share45.12-43.83-47.95-51.39-39.25-
Price to Earnings Ratio-211.54--61.67-22.85-7.41-7.73-
Price-to-Total Gains Ratio-12,664.36--3,256.38-28.06--609.69--502.06-
Price to Book Ratio4.18-4.06-4.80-6.73-5.49-
Price-to-Total Gains Ratio-12,664.36--3,256.38-28.06--609.69--502.06-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share34.632
Number of shares28
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.561.10
Usd Book Value Change Per Share0.060.29
Usd Total Gains Per Share0.621.39
Gains per Quarter (28 shares)17.3738.84
Gains per Year (28 shares)69.50155.37
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
16375912332145
21251412824665300
31882119736997455
425028266492129610
531335335615162765
637542404738194920
7438494738612261075
8500565429842591230
95636361111072911385
106257068012303231540

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%10.02.00.083.3%18.02.00.090.0%27.02.00.093.1%27.02.00.093.1%
Book Value Change Per Share2.02.00.050.0%9.03.00.075.0%15.05.00.075.0%23.05.01.079.3%23.05.01.079.3%
Dividend per Share2.00.02.050.0%10.00.02.083.3%18.00.02.090.0%20.00.09.069.0%20.00.09.069.0%
Total Gains per Share2.02.00.050.0%10.02.00.083.3%18.02.00.090.0%26.02.01.089.7%26.02.01.089.7%

Fundamentals of Dermapharm Holding SE

About Dermapharm Holding SE

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription healthcare products, herbal extracts, and other pharmaceutical products. It offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. The company also provides medical devices under the bite away and Herpotherm names. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. The company was founded in 1991 and is based in Grünwald, Germany. Dermapharm Holding SE operates as a subsidiary of Themis Beteiligungs-AG.

Fundamental data was last updated by Penke on 2024-04-21 04:49:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is overpriced.

1.1. Profitability of Dermapharm Holding SE.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Dermapharm Holding SE earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Dermapharm Holding SE to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -1.0% means that €-0.01 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Dermapharm Holding SE:

  • The MRQ is -1.0%. The company is making a loss. -1
  • The TTM is 4.9%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ-1.0%TTM4.9%-5.9%
TTM4.9%YOY13.1%-8.2%
TTM4.9%5Y12.3%-7.4%
5Y12.3%10Y13.3%-0.9%
1.1.2. Return on Assets

Shows how efficient Dermapharm Holding SE is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Dermapharm Holding SE to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.1% Return on Assets means that Dermapharm Holding SE generated €0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Dermapharm Holding SE:

  • The MRQ is -0.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 0.7%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-0.1%TTM0.7%-0.8%
TTM0.7%YOY2.3%-1.6%
TTM0.7%5Y2.1%-1.4%
5Y2.1%10Y2.8%-0.6%
1.1.3. Return on Equity

Shows how efficient Dermapharm Holding SE is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Dermapharm Holding SE to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.5% Return on Equity means Dermapharm Holding SE generated €0.00 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Dermapharm Holding SE:

  • The MRQ is -0.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 2.7%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-0.5%TTM2.7%-3.2%
TTM2.7%YOY6.6%-3.9%
TTM2.7%5Y7.2%-4.5%
5Y7.2%10Y11.3%-4.1%

1.2. Operating Efficiency of Dermapharm Holding SE.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Dermapharm Holding SE is operating .

  • Measures how much profit Dermapharm Holding SE makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Dermapharm Holding SE to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Dermapharm Holding SE:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM12.5%-12.5%
TTM12.5%YOY23.5%-11.0%
TTM12.5%5Y20.5%-8.0%
5Y20.5%10Y20.3%+0.2%
1.2.2. Operating Ratio

Measures how efficient Dermapharm Holding SE is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.22 means that the operating costs are €1.22 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Dermapharm Holding SE:

  • The MRQ is 1.220. The company is inefficient in keeping operating costs low. -1
  • The TTM is 0.934. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ1.220TTM0.934+0.286
TTM0.934YOY0.766+0.168
TTM0.9345Y0.809+0.125
5Y0.80910Y0.8100.000

1.3. Liquidity of Dermapharm Holding SE.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Dermapharm Holding SE is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.60 means the company has €1.60 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Dermapharm Holding SE:

  • The MRQ is 1.598. The company is able to pay all its short-term debts. +1
  • The TTM is 1.939. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.598TTM1.939-0.341
TTM1.939YOY2.548-0.608
TTM1.9395Y2.505-0.565
5Y2.50510Y2.267+0.238
1.3.2. Quick Ratio

Measures if Dermapharm Holding SE is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Dermapharm Holding SE to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.23 means the company can pay off €0.23 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Dermapharm Holding SE:

  • The MRQ is 0.232. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.798. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.232TTM0.798-0.566
TTM0.798YOY1.235-0.436
TTM0.7985Y1.187-0.388
5Y1.18710Y1.191-0.004

1.4. Solvency of Dermapharm Holding SE.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Dermapharm Holding SE assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Dermapharm Holding SE to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.75 means that Dermapharm Holding SE assets are financed with 74.8% credit (debt) and the remaining percentage (100% - 74.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Dermapharm Holding SE:

  • The MRQ is 0.748. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.745. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.748TTM0.745+0.003
TTM0.745YOY0.647+0.099
TTM0.7455Y0.710+0.035
5Y0.71010Y0.723-0.012
1.4.2. Debt to Equity Ratio

Measures if Dermapharm Holding SE is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Dermapharm Holding SE to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 299.6% means that company has €3.00 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Dermapharm Holding SE:

  • The MRQ is 2.996. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.935. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.996TTM2.935+0.061
TTM2.935YOY1.847+1.088
TTM2.9355Y2.544+0.392
5Y2.54410Y2.831-0.288

2. Market Valuation of Dermapharm Holding SE

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Dermapharm Holding SE generates.

  • Above 15 is considered overpriced but always compare Dermapharm Holding SE to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -211.54 means the investor is paying €-211.54 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Dermapharm Holding SE:

  • The EOD is -162.379. Based on the earnings, the company is expensive. -2
  • The MRQ is -211.543. Based on the earnings, the company is expensive. -2
  • The TTM is -61.668. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-162.379MRQ-211.543+49.163
MRQ-211.543TTM-61.668-149.875
TTM-61.668YOY22.851-84.519
TTM-61.6685Y7.410-69.078
5Y7.41010Y7.730-0.320
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Dermapharm Holding SE:

  • The EOD is 8.131. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 10.593. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 60.301. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD8.131MRQ10.593-2.462
MRQ10.593TTM60.301-49.708
TTM60.301YOY16.325+43.976
TTM60.3015Y40.526+19.775
5Y40.52610Y29.629+10.897
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Dermapharm Holding SE is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 4.18 means the investor is paying €4.18 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Dermapharm Holding SE:

  • The EOD is 3.210. Based on the equity, the company is fair priced.
  • The MRQ is 4.182. Based on the equity, the company is fair priced.
  • The TTM is 4.060. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.210MRQ4.182-0.972
MRQ4.182TTM4.060+0.122
TTM4.060YOY4.802-0.742
TTM4.0605Y6.725-2.665
5Y6.72510Y5.489+1.236
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Dermapharm Holding SE compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0030.058-106%0.165-102%0.271-101%0.349-101%
Book Value Per Share--10.12310.1730%9.410+8%7.568+34%6.010+68%
Current Ratio--1.5981.939-18%2.548-37%2.505-36%2.267-29%
Debt To Asset Ratio--0.7480.745+0%0.647+16%0.710+5%0.723+3%
Debt To Equity Ratio--2.9962.935+2%1.847+62%2.544+18%2.831+6%
Dividend Per Share---0.524-100%2.167-100%1.031-100%0.764-100%
Eps---0.0500.290-117%0.622-108%0.527-109%0.493-110%
Free Cash Flow Per Share--0.9990.826+21%1.158-14%0.705+42%0.594+68%
Free Cash Flow To Equity Per Share--0.9991.902-47%0.230+334%0.817+22%0.766+30%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--35.834--------
Intrinsic Value_10Y_min--31.132--------
Intrinsic Value_1Y_max--3.785--------
Intrinsic Value_1Y_min--3.718--------
Intrinsic Value_3Y_max--11.225--------
Intrinsic Value_3Y_min--10.719--------
Intrinsic Value_5Y_max--18.486--------
Intrinsic Value_5Y_min--17.171--------
Market Cap1749800000.000-30%2279585600.0002216986718.200+3%2427428549.750-6%2606939499.031-13%1991249733.793+14%
Net Profit Margin---0.0100.049-120%0.131-108%0.123-108%0.133-108%
Operating Margin---0.125-100%0.235-100%0.205-100%0.203-100%
Operating Ratio--1.2200.934+31%0.766+59%0.809+51%0.810+51%
Pb Ratio3.210-30%4.1824.060+3%4.802-13%6.725-38%5.489-24%
Pe Ratio-162.379+23%-211.543-61.668-71%22.851-1026%7.410-2955%7.730-2837%
Price Per Share32.500-30%42.34041.135+3%45.000-6%48.229-12%36.834+15%
Price To Free Cash Flow Ratio8.131-30%10.59360.301-82%16.325-35%40.526-74%29.629-64%
Price To Total Gains Ratio-9721.111+23%-12664.364-3256.380-74%28.060-45234%-609.687-95%-502.063-96%
Quick Ratio--0.2320.798-71%1.235-81%1.187-80%1.191-80%
Return On Assets---0.0010.007-117%0.023-105%0.021-106%0.028-104%
Return On Equity---0.0050.027-119%0.066-108%0.072-107%0.113-104%
Total Gains Per Share---0.0030.582-101%2.332-100%1.302-100%1.113-100%
Usd Book Value--580803148.800584142472.800-1%540694497.600+7%435566664.000+33%346053710.234+68%
Usd Book Value Change Per Share---0.0040.062-106%0.176-102%0.289-101%0.372-101%
Usd Book Value Per Share--10.78810.8400%10.027+8%8.064+34%6.405+68%
Usd Dividend Per Share---0.558-100%2.309-100%1.099-100%0.814-100%
Usd Eps---0.0530.309-117%0.663-108%0.561-109%0.525-110%
Usd Free Cash Flow--57330345.60047387498.400+21%66471861.600-14%40548157.920+41%34192972.800+68%
Usd Free Cash Flow Per Share--1.0650.880+21%1.234-14%0.751+42%0.633+68%
Usd Free Cash Flow To Equity Per Share--1.0652.027-47%0.245+334%0.871+22%0.817+30%
Usd Market Cap1864586880.000-30%2429126415.3602362421046.914+3%2586667862.614-6%2777954730.167-13%2121875716.330+14%
Usd Price Per Share34.632-30%45.11843.833+3%47.952-6%51.393-12%39.250+15%
Usd Profit---2870726.40016614568.800-117%35760470.400-108%30327455.520-109%27373169.545-110%
Usd Revenue--286431148.800302457506.400-5%273000326.400+5%244967960.160+17%211743722.483+35%
Usd Total Gains Per Share---0.0040.621-101%2.485-100%1.387-100%1.186-100%
 EOD+4 -4MRQTTM+8 -27YOY+10 -255Y+13 -2210Y+15 -20

3.2. Fundamental Score

Let's check the fundamental score of Dermapharm Holding SE based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-162.379
Price to Book Ratio (EOD)Between0-13.210
Net Profit Margin (MRQ)Greater than0-0.010
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.232
Current Ratio (MRQ)Greater than11.598
Debt to Asset Ratio (MRQ)Less than10.748
Debt to Equity Ratio (MRQ)Less than12.996
Return on Equity (MRQ)Greater than0.15-0.005
Return on Assets (MRQ)Greater than0.05-0.001
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Dermapharm Holding SE based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.888
Ma 20Greater thanMa 5032.727
Ma 50Greater thanMa 10035.277
Ma 100Greater thanMa 20037.894
OpenGreater thanClose32.850
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Interest Income  20,051-19,62642512,89313,318-12,405913-5,604-4,691



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets2,160,673
Total Liabilities1,615,625
Total Stockholder Equity539,207
 As reported
Total Liabilities 1,615,625
Total Stockholder Equity+ 539,207
Total Assets = 2,160,673

Assets

Total Assets2,160,673
Total Current Assets630,496
Long-term Assets1,530,176
Total Current Assets
Cash And Cash Equivalents 158,794
Short-term Investments 783
Net Receivables 90,935
Inventory 317,406
Other Current Assets 10,926
Total Current Assets  (as reported)630,496
Total Current Assets  (calculated)578,844
+/- 51,652
Long-term Assets
Property Plant Equipment 330,771
Goodwill 578,521
Intangible Assets 544,860
Long-term Assets  (as reported)1,530,176
Long-term Assets  (calculated)1,454,152
+/- 76,024

Liabilities & Shareholders' Equity

Total Current Liabilities394,489
Long-term Liabilities1,221,136
Total Stockholder Equity539,207
Total Current Liabilities
Short Long Term Debt 111,434
Accounts payable 86,641
Other Current Liabilities 7,685
Total Current Liabilities  (as reported)394,489
Total Current Liabilities  (calculated)205,760
+/- 188,729
Long-term Liabilities
Long term Debt 950,705
Capital Lease Obligations Min Short Term Debt18,249
Long-term Liabilities Other 2,655
Long-term Liabilities  (as reported)1,221,136
Long-term Liabilities  (calculated)971,609
+/- 249,527
Total Stockholder Equity
Retained Earnings 367,223
Total Stockholder Equity (as reported)539,207
Total Stockholder Equity (calculated)367,223
+/- 171,984
Other
Capital Stock53,840
Common Stock Shares Outstanding 53,840
Net Debt 903,345
Net Invested Capital 1,601,346
Net Working Capital 236,007
Property Plant and Equipment Gross 487,340



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
311,699
0
0
428,647
415,303
679,401
688,398
691,356
704,581
961,826
960,616
1,015,688
1,044,871
1,087,812
1,202,275
1,221,263
1,224,396
1,276,790
1,277,618
1,340,489
1,406,969
1,461,323
1,416,653
1,451,426
1,412,836
2,168,013
2,113,521
2,159,323
2,160,673
2,160,6732,159,3232,113,5212,168,0131,412,8361,451,4261,416,6531,461,3231,406,9691,340,4891,277,6181,276,7901,224,3961,221,2631,202,2751,087,8121,044,8711,015,688960,616961,826704,581691,356688,398679,401415,303428,64700311,699
   > Total Current Assets 
156,959
0
0
200,320
192,870
328,656
351,319
353,511
371,238
305,667
302,747
315,385
352,941
398,978
395,995
412,038
400,052
454,190
427,162
462,453
519,222
504,301
502,066
543,213
533,947
676,288
602,190
627,543
630,496
630,496627,543602,190676,288533,947543,213502,066504,301519,222462,453427,162454,190400,052412,038395,995398,978352,941315,385302,747305,667371,238353,511351,319328,656192,870200,32000156,959
       Cash And Cash Equivalents 
3,816
0
0
12,578
6,286
139,702
180,059
196,318
212,810
82,265
81,672
67,855
114,980
138,694
97,695
105,493
120,623
145,745
101,447
118,682
160,319
127,547
83,775
130,597
149,918
213,149
110,778
117,428
158,794
158,794117,428110,778213,149149,918130,59783,775127,547160,319118,682101,447145,745120,623105,49397,695138,694114,98067,85581,67282,265212,810196,318180,059139,7026,28612,578003,816
       Short-term Investments 
30
0
0
68,658
400
38,014
1,062
1,861
1,101
1,684
2,485
4,913
1,056
4,683
4,053
4,529
1,037
3,360
3,940
12,372
11,742
4,971
14,883
15,287
11,440
13,720
23,510
25,190
783
78325,19023,51013,72011,44015,28714,8834,97111,74212,3723,9403,3601,0374,5294,0534,6831,0564,9132,4851,6841,1011,8611,06238,01440068,6580030
       Net Receivables 
68,076
0
0
35,104
104,763
38,430
46,753
41,751
41,127
54,177
59,591
58,516
64,282
62,264
68,807
67,290
70,571
73,100
78,522
82,415
104,179
91,346
112,202
107,564
117,163
108,468
113,236
127,088
90,935
90,935127,088113,236108,468117,163107,564112,20291,346104,17982,41578,52273,10070,57167,29068,80762,26464,28258,51659,59154,17741,12741,75146,75338,430104,76335,1040068,076
       Inventory 
84,582
0
0
81,938
81,106
103,349
113,295
108,076
115,560
162,203
152,762
177,188
172,167
185,993
213,341
225,699
203,264
216,109
231,157
238,486
240,535
268,218
272,847
275,174
251,822
315,369
326,925
333,182
317,406
317,406333,182326,925315,369251,822275,174272,847268,218240,535238,486231,157216,109203,264225,699213,341185,993172,167177,188152,762162,203115,560108,076113,295103,34981,10681,9380084,582
       Other Current Assets 
485
0
0
2,042
315
9,161
10,150
5,505
640
5,338
6,237
6,913
456
7,344
12,099
9,027
4,557
15,876
12,096
10,498
2,447
12,219
18,359
14,591
3,604
25,582
27,741
24,655
10,926
10,92624,65527,74125,5823,60414,59118,35912,2192,44710,49812,09615,8764,5579,02712,0997,3444566,9136,2375,3386405,50510,1509,1613152,04200485
   > Long-term Assets 
154,740
0
0
228,327
222,433
350,745
337,079
337,845
333,343
656,160
657,869
700,303
691,930
688,834
806,280
809,226
824,345
822,600
850,456
878,036
887,747
957,022
914,587
908,212
878,890
1,491,726
1,511,331
1,531,780
1,530,176
1,530,1761,531,7801,511,3311,491,726878,890908,212914,587957,022887,747878,036850,456822,600824,345809,226806,280688,834691,930700,303657,869656,160333,343337,845337,079350,745222,433228,32700154,740
       Property Plant Equipment 
53,357
0
0
52,920
56,036
69,854
74,193
78,685
80,874
116,109
122,352
125,667
132,585
132,224
195,590
196,495
199,619
199,943
204,254
212,936
222,287
232,034
231,103
229,516
225,673
271,439
298,050
326,397
330,771
330,771326,397298,050271,439225,673229,516231,103232,034222,287212,936204,254199,943199,619196,495195,590132,224132,585125,667122,352116,10980,87478,68574,19369,85456,03652,9200053,357
       Goodwill 
17,033
0
0
17,033
24,583
130,067
52,310
54,429
54,621
169,775
171,993
207,372
202,244
202,245
250,724
252,613
266,268
266,346
266,352
266,397
264,730
324,351
282,408
282,683
271,319
834,541
578,354
582,171
578,521
578,521582,171578,354834,541271,319282,683282,408324,351264,730266,397266,352266,346266,268252,613250,724202,245202,244207,372171,993169,77554,62154,42952,310130,06724,58317,0330017,033
       Long Term Investments 
3,558
0
0
0
3,800
10,422
13,879
8,977
4,853
69,082
69,149
68,771
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000068,77169,14969,0824,8538,97713,87910,4223,8000003,558
       Intangible Assets 
70,025
0
0
129,682
133,404
134,347
195,216
195,754
189,934
301,194
294,375
298,494
293,030
290,680
296,940
297,440
297,342
295,583
294,083
291,820
294,841
293,864
310,844
305,843
305,043
310,023
569,940
562,093
544,860
544,860562,093569,940310,023305,043305,843310,844293,864294,841291,820294,083295,583297,342297,440296,940290,680293,030298,494294,375301,194189,934195,754195,216134,347133,404129,6820070,025
       Long-term Assets Other 
30
0
0
68,658
400
38,014
1,062
1,861
1,102
1,684
2,485
-1
1
1
4,053
1
1,037
3,360
1
12,372
11,742
4,971
14,884
15,286
1
75,723
23,510
25,190
0
025,19023,51075,723115,28614,8844,97111,74212,37213,3601,03714,05311-12,4851,6841,1021,8611,06238,01440068,6580030
> Total Liabilities 
250,893
0
0
359,159
341,618
479,323
471,068
447,737
448,496
685,836
705,621
750,315
760,381
776,744
920,987
917,811
899,814
915,915
912,824
914,541
907,135
924,953
961,430
945,877
880,344
1,586,959
1,592,124
1,614,095
1,615,625
1,615,6251,614,0951,592,1241,586,959880,344945,877961,430924,953907,135914,541912,824915,915899,814917,811920,987776,744760,381750,315705,621685,836448,496447,737471,068479,323341,618359,15900250,893
   > Total Current Liabilities 
115,423
0
0
86,231
80,576
184,218
186,728
105,239
146,398
347,882
171,415
178,742
102,421
118,207
137,102
134,239
132,872
148,848
159,042
160,830
155,613
169,569
227,913
212,057
217,792
294,433
300,282
337,952
394,489
394,489337,952300,282294,433217,792212,057227,913169,569155,613160,830159,042148,848132,872134,239137,102118,207102,421178,742171,415347,882146,398105,239186,728184,21880,57686,23100115,423
       Short-term Debt 
65,883
0
0
43,422
32,264
100,199
102,690
29,038
71,577
256,865
85,163
75,465
11,263
13,960
20,998
4,529
26,044
0
36,132
0
5,580
0
58,927
26,100
4,887
16,861
46,650
61,785
0
061,78546,65016,8614,88726,10058,92705,580036,132026,0444,52920,99813,96011,26375,46585,163256,86571,57729,038102,690100,19932,26443,4220065,883
       Short Long Term Debt 
162,789
0
0
0
18,640
100,199
88,899
22,683
65,334
229,179
81,986
50,031
8,214
0
17,162
0
22,205
0
32,487
0
2,379
0
55,642
0
1,869
0
41,687
0
111,434
111,434041,68701,869055,64202,379032,487022,205017,16208,21450,03181,986229,17965,33422,68388,899100,19918,640000162,789
       Accounts payable 
24,526
0
0
19,273
23,367
28,477
26,978
26,755
28,181
33,722
38,871
40,272
35,355
46,459
53,864
49,785
50,370
59,795
56,074
52,014
52,101
60,080
53,150
56,022
56,100
80,405
76,935
85,985
86,641
86,64185,98576,93580,40556,10056,02253,15060,08052,10152,01456,07459,79550,37049,78553,86446,45935,35540,27238,87133,72228,18126,75526,97828,47723,36719,2730024,526
       Other Current Liabilities 
619
0
0
11,485
746
20,192
22,632
19,028
1,373
19,631
26,634
33,367
5,540
27,533
27,838
84,454
1,675
89,053
28,738
108,816
1,320
109,489
115,836
156,035
1,464
214,028
55,203
251,967
7,685
7,685251,96755,203214,0281,464156,035115,836109,4891,320108,81628,73889,0531,67584,45427,83827,5335,54033,36726,63419,6311,37319,02822,63220,19274611,48500619
   > Long-term Liabilities 
135,470
0
0
272,928
261,042
295,105
284,340
342,498
302,098
337,954
534,206
571,573
657,960
658,537
783,885
783,572
766,942
767,067
753,782
753,711
751,522
755,384
733,517
733,820
662,552
1,292,526
1,291,842
1,276,143
1,221,136
1,221,1361,276,1431,291,8421,292,526662,552733,820733,517755,384751,522753,711753,782767,067766,942783,572783,885658,537657,960571,573534,206337,954302,098342,498284,340295,105261,042272,92800135,470
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
238,138
436,860
451,032
543,347
543,692
602,260
601,452
580,759
579,787
576,668
575,637
574,721
575,810
575,312
575,781
511,560
1,119,253
1,052,671
0
0
001,052,6711,119,253511,560575,781575,312575,810574,721575,637576,668579,787580,759601,452602,260543,692543,347451,032436,860238,138000000000
       Long term Debt 
96,753
0
0
0
222,346
221,150
218,692
277,942
232,551
238,138
428,012
451,032
533,592
543,692
591,159
601,452
570,483
579,787
567,376
575,637
565,708
575,810
564,892
575,781
501,844
1,119,253
1,040,560
0
950,705
950,70501,040,5601,119,253501,844575,781564,892575,810565,708575,637567,376579,787570,483601,452591,159543,692533,592451,032428,012238,138232,551277,942218,692221,150222,34600096,753
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
12,025
0
12,804
0
14,937
0
14,115
0
12,937
0
12,214
0
13,704
0
12,734
0
17,074
0
18,249
18,249017,074012,734013,704012,214012,937014,115014,937012,804012,0250000000000
       Other Liabilities 
38,574
0
0
0
38,559
73,955
65,564
64,556
69,355
99,816
97,346
120,541
114,613
114,845
181,625
182,120
186,183
187,280
177,114
178,074
176,801
179,574
158,205
158,039
150,992
0
239,171
241,752
0
0241,752239,1710150,992158,039158,205179,574176,801178,074177,114187,280186,183182,120181,625114,845114,613120,54197,34699,81669,35564,55665,56473,95538,55900038,574
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
10,602
10,653
10,277
11,915
12,106
10,797
10,809
11,221
11,666
10,952
11,102
2,411
12,212
11,206
11,031
1,992
12,972
12,332
13,243
2,655
2,65513,24312,33212,9721,99211,03111,20612,2122,41111,10210,95211,66611,22110,80910,79712,10611,91510,27710,65310,602000000000
       Deferred Long Term Liability 
25,875
0
0
0
35,516
0
0
0
39,990
0
0
0
51,978
0
0
0
62,103
0
0
0
77,717
0
0
0
0
0
0
0
0
0000000077,71700062,10300051,97800039,99000035,51600025,875
> Total Stockholder Equity
56,915
0
0
69,488
73,685
200,078
217,330
240,053
252,449
273,878
252,774
259,956
278,649
305,074
275,002
297,251
321,966
358,325
362,511
423,201
497,316
534,085
452,994
503,863
531,592
580,563
521,201
545,891
539,207
539,207545,891521,201580,563531,592503,863452,994534,085497,316423,201362,511358,325321,966297,251275,002305,074278,649259,956252,774273,878252,449240,053217,330200,07873,68569,4880056,915
   Common Stock
1,342
0
0
1,342
120
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
53,840
0
053,84053,84053,84053,84053,84053,84053,84053,84053,84053,84053,84053,84053,84053,84053,84053,84053,84053,84053,84053,84053,84053,84053,8401201,342001,342
   Retained Earnings 
56,274
0
0
70,037
25,669
47,055
63,658
85,971
100,993
122,231
101,089
120,340
139,067
165,731
136,036
158,688
177,082
213,393
205,832
266,306
337,954
375,325
273,011
325,466
355,357
404,762
345,073
369,917
367,223
367,223369,917345,073404,762355,357325,466273,011375,325337,954266,306205,832213,393177,082158,688136,036165,731139,067120,340101,089122,231100,99385,97163,65847,05525,66970,0370056,274
   Accumulated Other Comprehensive Income 
-45,052
0
0
0
-50,644
0
0
0
-90,650
0
0
0
-68,952
0
0
0
-85,454
0
0
0
0
0
0
23,766
21,605
21,171
21,498
21,344
0
021,34421,49821,17121,60523,766000000-85,454000-68,952000-90,650000-50,644000-45,052
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100,790
100,790
100,790
100,790
100,790
100,790
100,790
100,790
100,790
0
0
00100,790100,790100,790100,790100,790100,790100,790100,790100,790000000000000000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
44,351
0
0
-1,891
98,540
99,183
99,832
100,242
188,266
97,807
97,845
85,776
154,694
85,503
85,126
84,723
176,498
91,092
102,839
103,055
105,522
104,920
126,143
100,791
100,790
100,790
100,790
100,790
0
0100,790100,790100,790100,790100,791126,143104,920105,522103,055102,83991,092176,49884,72385,12685,503154,69485,77697,84597,807188,266100,24299,83299,18398,540-1,8910044,351



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,135,351
Cost of Revenue-416,191
Gross Profit719,160719,160
 
Operating Income (+$)
Gross Profit719,160
Operating Expense-955,250
Operating Income180,101-236,090
 
Operating Expense (+$)
Research Development10,628
Selling General Administrative95,283
Selling And Marketing Expenses-
Operating Expense955,250105,911
 
Net Interest Income (+$)
Interest Income2,494
Interest Expense-54,968
Other Finance Cost-17,260
Net Interest Income-69,734
 
Pretax Income (+$)
Operating Income180,101
Net Interest Income-69,734
Other Non-Operating Income Expenses-
Income Before Tax (EBT)105,997180,101
EBIT - interestExpense = -54,968
62,368
117,336
Interest Expense54,968
Earnings Before Interest and Taxes (EBIT)-160,965
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax105,997
Tax Provision-45,462
Net Income From Continuing Ops60,53460,535
Net Income62,368
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-69,734
 

Technical Analysis of Dermapharm Holding SE
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Dermapharm Holding SE. The general trend of Dermapharm Holding SE is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Dermapharm Holding SE's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Dermapharm Holding SE.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 34.10 < 34.40 < 34.96.

The bearish price targets are: 31.50 > 31.50.

Tweet this
Dermapharm Holding SE Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Dermapharm Holding SE. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Dermapharm Holding SE Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Dermapharm Holding SE. The current macd is -0.81156655.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Dermapharm Holding SE price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Dermapharm Holding SE. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Dermapharm Holding SE price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Dermapharm Holding SE Daily Moving Average Convergence/Divergence (MACD) ChartDermapharm Holding SE Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Dermapharm Holding SE. The current adx is 23.05.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Dermapharm Holding SE shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Dermapharm Holding SE Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Dermapharm Holding SE. The current sar is 33.70.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Dermapharm Holding SE Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Dermapharm Holding SE. The current rsi is 41.89. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Dermapharm Holding SE Daily Relative Strength Index (RSI) ChartDermapharm Holding SE Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Dermapharm Holding SE. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Dermapharm Holding SE price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Dermapharm Holding SE Daily Stochastic Oscillator ChartDermapharm Holding SE Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Dermapharm Holding SE. The current cci is -2.54312144.

Dermapharm Holding SE Daily Commodity Channel Index (CCI) ChartDermapharm Holding SE Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Dermapharm Holding SE. The current cmo is -10.6614006.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Dermapharm Holding SE Daily Chande Momentum Oscillator (CMO) ChartDermapharm Holding SE Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Dermapharm Holding SE. The current willr is -51.61290323.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Dermapharm Holding SE is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Dermapharm Holding SE Daily Williams %R ChartDermapharm Holding SE Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Dermapharm Holding SE.

Dermapharm Holding SE Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Dermapharm Holding SE. The current atr is 0.87455741.

Dermapharm Holding SE Daily Average True Range (ATR) ChartDermapharm Holding SE Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Dermapharm Holding SE. The current obv is -228,974.

Dermapharm Holding SE Daily On-Balance Volume (OBV) ChartDermapharm Holding SE Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Dermapharm Holding SE. The current mfi is 63.68.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Dermapharm Holding SE Daily Money Flow Index (MFI) ChartDermapharm Holding SE Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Dermapharm Holding SE.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-20BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-03MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Dermapharm Holding SE Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Dermapharm Holding SE based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.888
Ma 20Greater thanMa 5032.727
Ma 50Greater thanMa 10035.277
Ma 100Greater thanMa 20037.894
OpenGreater thanClose32.850
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Dermapharm Holding SE with someone you think should read this too:
  • Are you bullish or bearish on Dermapharm Holding SE? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Dermapharm Holding SE? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Dermapharm Holding SE

I send you an email if I find something interesting about Dermapharm Holding SE.


Comments

How you think about this?

Leave a comment

Stay informed about Dermapharm Holding SE.

Receive notifications about Dermapharm Holding SE in your mailbox!